CO2021001064A2 - Método para la producción de las células t gamma delta - Google Patents

Método para la producción de las células t gamma delta

Info

Publication number
CO2021001064A2
CO2021001064A2 CONC2021/0001064A CO2021001064A CO2021001064A2 CO 2021001064 A2 CO2021001064 A2 CO 2021001064A2 CO 2021001064 A CO2021001064 A CO 2021001064A CO 2021001064 A2 CO2021001064 A2 CO 2021001064A2
Authority
CO
Colombia
Prior art keywords
production
cells
gamma delta
cell
pluripotent stem
Prior art date
Application number
CONC2021/0001064A
Other languages
English (en)
Inventor
Shin Kaneko
Shoichi Iriguchi
Tatsuki Ueda
Yoshiaki Kassai
Akira Hayashi
Kazuhide Nakayama
Original Assignee
Takeda Pharmaceuticals Co
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Univ Kyoto filed Critical Takeda Pharmaceuticals Co
Publication of CO2021001064A2 publication Critical patent/CO2021001064A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

RESUMEN La presente invención proporciona un método para la producción de una célula γδT a partir de una célula madre pluripotente inducida, en donde la célula madre pluripotente inducida se deriva a partir de una célula diferente de una célula αßT.
CONC2021/0001064A 2018-07-13 2021-01-29 Método para la producción de las células t gamma delta CO2021001064A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018133727 2018-07-13
JP2019117891 2019-06-25
PCT/JP2019/027697 WO2020013315A1 (ja) 2018-07-13 2019-07-12 γδＴ細胞の製造方法

Publications (1)

Publication Number Publication Date
CO2021001064A2 true CO2021001064A2 (es) 2021-02-08

Family

ID=69143058

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0001064A CO2021001064A2 (es) 2018-07-13 2021-01-29 Método para la producción de las células t gamma delta

Country Status (14)

Country Link
US (1) US20210130777A1 (es)
EP (1) EP3822342A4 (es)
JP (1) JP7479635B2 (es)
KR (1) KR20210030373A (es)
CN (1) CN112513256A (es)
AU (1) AU2019302207A1 (es)
BR (1) BR112021000437A2 (es)
CA (1) CA3106089A1 (es)
CO (1) CO2021001064A2 (es)
IL (1) IL280041A (es)
MX (1) MX2021000459A (es)
SG (1) SG11202100260QA (es)
TW (1) TW202020145A (es)
WO (1) WO2020013315A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109337870B (zh) * 2018-12-24 2020-07-03 广东暨德康民生物科技有限责任公司 人Vγ9Vδ2T细胞扩增方法与培养基
EP4069827A4 (en) * 2019-12-06 2024-05-29 Fate Therapeutics Inc ENHANCEMENT OF AN IPSC-DERIVED IMMUNE EFFECTOR CELL USING SMALL COMPOUNDS
EP4170020A1 (en) 2020-06-17 2023-04-26 Kyoto University Chimeric antigen receptor-expressing immunocompetent cells
CN116964194A (zh) * 2021-02-05 2023-10-27 国立大学法人神户大学 诱导性多能干细胞衍生的γδT细胞及其产生方法
CA3214045A1 (en) * 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
CN113583955A (zh) * 2021-08-24 2021-11-02 羽铂精制生物技术(成都)有限公司 一种因子法扩增t细胞的培养基及培养方法
WO2023086968A2 (en) * 2021-11-12 2023-05-19 Janssen Biotech, Inc. Materials and methods for improved expansion and uses of immune cells
WO2023194915A1 (en) * 2022-04-04 2023-10-12 Gammadelta Therapeutics Ltd Novel gene armoring
WO2023194911A1 (en) * 2022-04-04 2023-10-12 Gammadelta Therapeutics Ltd Cells expressing an anti-mesothelin car

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
EP1268746B1 (en) 2000-04-03 2009-11-18 Therapure Biopharma Inc. PRODUCTION OF TcR GAMMA DELTA T CELLS
US9453219B2 (en) 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
WO2006006720A1 (ja) 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
AU2006325975B2 (en) 2005-12-13 2011-12-08 Kyoto University Nuclear reprogramming factor
KR101516833B1 (ko) 2007-03-23 2015-05-07 위스콘신 얼럼나이 리서어치 화운데이션 체세포 재프로그래밍
EP3031916B1 (en) 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP3078738B1 (en) 2007-08-31 2020-05-20 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2009057831A1 (ja) 2007-10-31 2009-05-07 Kyoto University 核初期化方法
AU2008286249B2 (en) 2007-12-10 2013-10-10 Kyoto University Efficient method for nuclear reprogramming
EP2242838A1 (en) 2007-12-17 2010-10-27 GliaMed, Inc. Stem-like cells and method for reprogramming adult mammalian somatic cells
WO2009091659A2 (en) 2008-01-16 2009-07-23 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents
EP2250252A2 (en) 2008-02-11 2010-11-17 Cambridge Enterprise Limited Improved reprogramming of mammalian cells, and the cells obtained
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
US20110014164A1 (en) 2008-02-15 2011-01-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
AU2009225665B9 (en) 2008-03-17 2015-01-15 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
WO2009114949A1 (en) 2008-03-20 2009-09-24 UNIVERSITé LAVAL Methods for deprogramming somatic cells and uses thereof
AU2009233845A1 (en) 2008-04-07 2009-10-15 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of a small molecule modulator
CA2695590C (en) 2008-06-27 2018-01-09 Kyoto University Method of efficiently establishing induced pluripotent stem cells
JP4281071B1 (ja) * 2008-07-10 2009-06-17 学校法人兵庫医科大学 Ｖγ９Ｖδ２Ｔ細胞の増殖剤、活性化Ｖγ９Ｖδ２Ｔ細胞の製造方法およびこれらの利用
JP2011527905A (ja) 2008-07-14 2011-11-10 オクラホマ・メディカル・リサーチ・ファウンデーション Ｂｒｉｇｈｔ／ａｒｉｄ３ａ機能の阻害による多能性細胞の作製方法
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
WO2010042800A1 (en) 2008-10-10 2010-04-15 Nevada Cancer Institute Methods of reprogramming somatic cells and methods of use for such cells
WO2010050626A1 (en) 2008-10-30 2010-05-06 Kyoto University Method for producing induced pluripotent stem cells
US20110059526A1 (en) 2008-11-12 2011-03-10 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
EP2376626A4 (en) 2008-12-13 2012-10-17 Dna Microarray MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS)
CA2753845C (en) 2009-02-27 2019-10-29 Kyoto University Nuclear reprogramming substance comprising glis1
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
WO2010111409A2 (en) 2009-03-25 2010-09-30 The Salk Institute For Biological Studies Pluripotent stem cells
US20120076762A1 (en) 2009-03-25 2012-03-29 The Salk Institute For Biological Studies Induced pluripotent stem cell generation using two factors and p53 inactivation
WO2010115050A2 (en) 2009-04-01 2010-10-07 The Regents Of The University Of California Embryonic stem cell specific micrornas promote induced pluripotency
WO2010124290A2 (en) 2009-04-24 2010-10-28 Whitehead Institute For Biomedical Research Compositions and methods for deriving or culturing pluripotent cells
CA2764373C (en) 2009-06-05 2019-11-19 Cellular Dynamics International, Inc. Reprogramming t cells and hematophietic cells
WO2010147395A2 (en) 2009-06-16 2010-12-23 Korea Research Institute Of Bioscience And Biotechnology Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same
US9834754B2 (en) 2011-11-21 2017-12-05 University Health Network Populations of hematopoietic progenitors and methods of enriching stem cells therefor
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
AU2015290561A1 (en) 2014-07-18 2017-03-09 Hiroshi Kawamoto Method for generating pluripotent stem cells bearing antigen specific T cell receptor genes
EP3536707A1 (en) * 2014-11-05 2019-09-11 Board of Regents, The University of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
EP3219791A4 (en) 2014-11-13 2018-07-18 Kyoto University Method for induction of t cells from pluripotent stem cells
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure
CN108463548B (zh) * 2015-10-30 2023-04-18 加利福尼亚大学董事会 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法
EP3476934A4 (en) 2016-06-23 2020-02-26 Kyoto University METHOD FOR PRODUCING CD4 / CD8 POSITIVE DUAL T CELLS
EP4053268A3 (en) 2017-01-20 2022-12-07 Kyoto University Method for producing cd8alpha+beta+cytotoxic t cells
WO2018143243A1 (ja) * 2017-02-03 2018-08-09 国立大学法人神戸大学 人工多能性幹細胞の作製方法
CN110691844B (zh) * 2017-02-07 2023-09-08 新加坡科技研究局 从多能干细胞产生模拟的先天免疫细胞的方法和试剂盒
JP2018133727A (ja) 2017-02-16 2018-08-23 富士通株式会社 無線通信システム、無線通信装置、及びビームパターン決定方法
JP7109916B2 (ja) 2017-12-27 2022-08-01 株式会社ディスコ 分割装置

Also Published As

Publication number Publication date
SG11202100260QA (en) 2021-02-25
CA3106089A1 (en) 2020-01-16
EP3822342A4 (en) 2022-08-03
BR112021000437A2 (pt) 2021-04-06
JP7479635B2 (ja) 2024-05-09
AU2019302207A1 (en) 2021-03-04
JPWO2020013315A1 (ja) 2021-08-02
IL280041A (en) 2021-03-01
EP3822342A1 (en) 2021-05-19
MX2021000459A (es) 2021-06-23
US20210130777A1 (en) 2021-05-06
CN112513256A (zh) 2021-03-16
TW202020145A (zh) 2020-06-01
KR20210030373A (ko) 2021-03-17
WO2020013315A1 (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
CO2021001064A2 (es) Método para la producción de las células t gamma delta
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
BR112022001207A2 (pt) Método de obtenção de mitocôndrias de células e mitocôndrias obtidas
TW201612312A (en) Meristematic plant cells and method of isolating them
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
TW201643242A (en) Systems and methods for growing and harvesting cells
WO2016168890A8 (en) Generation of muscle-lineage cells from stem cells
BR112022001416A2 (pt) Populações de células t gama delta ex vivo
MY193954A (en) Method for manufacturing ciliary margin stem cells
EA202090766A1 (ru) Крупномасштабное производство жидких и твердых продуктов на основе trichoderma
SG10201806655TA (en) Microorganism producing o-acetyl-homoserine and method for producing o-acetylhomoserine using the same
SG11201907720RA (en) Method for the alignment of two substrates
WO2019027173A3 (ko) 신규한 싸이코스-6-인산 탈인산효소, 상기 효소를 포함하는 사이코스 생산용 조성물, 상기 효소를 이용하여 사이코스를 제조하는 방법
MX2021001528A (es) Metodo para la produccion de celulas positivas para cd3.
WO2016005985A3 (en) Method for reprogramming cells
DK3436568T3 (da) Kulturmedium til pluripotente stamceller
IL294152A (en) A method for culturing hematopoietic stem cells
AR113695A1 (es) Una d-psicosa 3-epimerasa y el uso de un método para producir d-psicosa
AR120099A1 (es) Cepa de levadura que produce glutatión y procedimiento para producir glutatión usando la misma
BR112016016397A2 (pt) método para preparar 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carbaldeídos e 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carboxilatos.
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo
CO2020002617A2 (es) Método para la producción de plántulas de caña de azúcar
MX2021006808A (es) Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma.
EA202092707A1 (ru) Огнеупор, шихта для его получения, способ его получения, а также применение такого огнеупора
PH12018502672A1 (en) Method for increasing nitrogen-use efficiency and or nitrogen-utilisation efficiency in plants